The properties of cyproheptadine as an anti-spastic agent have been reporte
d since 1980. In this study we sought to investigate whether gait function,
as specified by stride length, cadence, heart rate, and also by questionna
ire, correlated with cyproheptadine medication during a double-blind matche
d-placebo cross-over trial, undertaken on a group of 16 hemiplegic spastic
patients aged 4-18 years. We found that neither qualitative nor quantitativ
e analyses suggested any systematic change in gait parameters dependent on
cyproheptadine medication. We conclude that our study on 16 patients showed
no statistical evidence of improvement in spasticity due to the action of
cyproheptadine. An effect was, however, found in the case of mean patient h
eart rate, which was 10% higher (P < 0.003) at the end of the cyproheptadin
e medication period. (C) 1998 Elsevier Science B.V. All rights reserved.